Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
International Journal of Hematology
Published in: International Journal of Hematology 1/2007

01-01-2007

Clinical Features of Hypereosinophilic Syndrome: FIP1L1-PDGFRA Fusion Gene—Positive Disease is a Distinct Clinical Entity with Myeloproliferative Features and a Poor Response to Corticosteroid

Authors: Keisuke Miyazawa, Naoki Kakazu, Kazuma Ohyashiki

Published in: International Journal of Hematology | Issue 1/2007

Login to get access
Metadata
Title
Clinical Features of Hypereosinophilic Syndrome: FIP1L1-PDGFRA Fusion Gene—Positive Disease is a Distinct Clinical Entity with Myeloproliferative Features and a Poor Response to Corticosteroid
Authors
Keisuke Miyazawa
Naoki Kakazu
Kazuma Ohyashiki
Publication date
01-01-2007
Publisher
Springer Japan
Published in
International Journal of Hematology / Issue 1/2007
Print ISSN: 0925-5710
Electronic ISSN: 1865-3774
DOI
https://doi.org/10.1532/IJH97.06047

Other articles of this Issue 1/2007

International Journal of Hematology 1/2007 Go to the issue

Case report

Superficial Fibromatosis Mimicking Subcutaneous Hematoma: An Unusual and Difficult Diagnosis in a Patient with Mild Hemophilia A

OriginalPaper

Aggressive Natural Killer Cell Leukemia: Report of a Chinese Series and Review of the Literature

OriginalPaper

Survival Outcome after the First Central Nervous System Relapse in Children with Acute Lymphoblastic Leukemia: A Retrospective Analysis of 79 Patients in a Joint Program Involving the Experience of Three Japanese Study Groups

OriginalPaper

Treatment of Myelodysplastic Syndrome with Cyclosporin A

OriginalPaper

Induction of Multilineage Markers in Human Myeloma Cells and Their Down-Regulation by Interleukin 6

OriginalPaper

Clinicopathologic Significance of Loss of CD19 Expression in Diffuse Large B-Cell Lymphoma
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits